Clinical Study Results
Research Sponsor: AstraZeneca AB
Drugs Studied: Dapagliflozin and saxagliptin
National Clinical Trial #: NCT02471404
Eudra CT #: 2015-002376-24
Protocol #: D1689C00014
Study Date: September 2015 to March 2017
Short Study Title: A study to learn if dapagliflozin or dapagliflozin plus
saxagliptin are as effective and safe as glimepiride
in treating patients with type 2 diabetes.
Thank you!
As a clinical study participant, you belong to a large community of participants around the
world. You help researchers answer important health questions and discover new medical
treatments.
Thank you for taking part in this clinical study for the drugs dapagliflozin and saxagliptin.
You and all of the other participants helped researchers learn how effective and safe
these drugs are for treating patients with type 2 diabetes.
AstraZeneca AB, the sponsor of this study, thanks you for your help and thinks it
is important for you to know the results of your study. An independent, non-profit
organization called CISCRP prepared this summary of the study results for you with the
help of a medical writing organization.
We hope this summary helps you understand and feel proud of your important role in
medical research. If you have questions about the results, please speak with the study
doctors or staff at your study site.
Whatâ€™s happened since my study ended?
Your study started in September 2015 and ended in March 2017. It included 937
participants at 194 study sites in the Czech Republic, Germany, Hungary, Poland, and
Slovakia. When the study ended, the sponsor reviewed the data and created a report of
the results. This is a summary of that report.